Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1292

Special Issue Editor


E-Mail Website
Guest Editor
EA4340-BCOH, Biomarker in Cancerology and Onco-Haematology, Université de Versailles-Saint-Quentin-En-Yvelines, Université Paris Saclay, 92100 Boulogne-Billancourt, France
Interests: immunotherapy; immunology; cancer and cell biology; targeted therapies; biomarkers; developmental pathways
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The use of immune checkpoint inhibitors (ICIs) including anti-PDL-1/PD-1 (Pembroluzimab, nivolumab, atezolizumab, avelumab, durvalumab), and anti-CTL4 (Ipilimumab), has shown promising results in various types of refractory solid and hematological malignancies such as melanoma, lung cancers, leukemia, and lymphoma. To fully exploit the potential of ICIs and uncover why some patients are still refractory to these promising drugs, studies are implemented to understand the molecular and cellular mechanisms related to ICI resistance or efficacy.

This Special Issue aims to address the latest findings related to the use of ICI-based immunotherapy in cancer, including treatment schedule, mechanisms of ICIs resistance, and predictive biomarkers.

Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcome. All manuscripts will follow the standard journal peer review practices, and those accepted for publication will appear in this Special Issue on “Immune-Checkpoints-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance”. We look forward to receiving your contributions.

You may choose our Joint Special Issue in Vaccines.

Dr. Paul Takam Kamga
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • immunotherapy
  • ICIs
  • immuno-resistance
  • predictive biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

5 pages, 220 KiB  
Editorial
Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
by Giada Dal Collo and Paul Takam Kamga
Cancers 2023, 15(18), 4503; https://doi.org/10.3390/cancers15184503 - 10 Sep 2023
Cited by 1 | Viewed by 968
Abstract
Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response [...] Full article
Back to TopTop